Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 25
1996 78
1997 80
1998 143
1999 156
2000 144
2001 137
2002 127
2003 152
2004 182
2005 162
2006 194
2007 240
2008 262
2009 208
2010 246
2011 243
2012 245
2013 233
2014 264
2015 231
2016 255
2017 204
2018 208
2019 158
2020 490
2021 268
2022 304
2023 344
2024 205

Text availability

Article attribute

Article type

Publication date

Search Results

5,623 results

Results by year

Filters applied: . Clear all
Page 1
VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, Gao Y, Cui Z, Zhang Q, Meng X, Gui H, Wang W, Jiang Y, Song Z, Shi Y, Sun J, Zhang Y, Xie Q, Xu Y, Ning G, Gao Y, Zhao R. Cao Z, et al. N Engl J Med. 2023 Feb 2;388(5):406-417. doi: 10.1056/NEJMoa2208822. Epub 2022 Dec 28. N Engl J Med. 2023. PMID: 36577095 Free PMC article. Clinical Trial.
Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
Anderson AS, Caubel P, Rusnak JM; EPIC-HR Trial Investigators. Anderson AS, et al. N Engl J Med. 2022 Sep 15;387(11):1047-1049. doi: 10.1056/NEJMc2205944. Epub 2022 Sep 7. N Engl J Med. 2022. PMID: 36069818 Free PMC article. No abstract available.
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S, Metzendorf MI, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S. Reis S, et al. Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2023 Nov 30;11:CD015395. doi: 10.1002/14651858.CD015395.pub3. PMID: 36126225 Free PMC article. Updated. Review.
Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk.
Paraskevis D, Gkova M, Mellou K, Gerolymatos G, Psalida N, Gkolfinopoulou K, Kostaki EG, Loukides S, Kotanidou A, Skoutelis A, Thiraios E, Saroglou G, Zografopoulos D, Filippou D, Mossialos E, Zaoutis T, Gaga M, Tsiodras S, Antoniadou A. Paraskevis D, et al. J Infect Dis. 2023 Dec 20;228(12):1667-1674. doi: 10.1093/infdis/jiad324. J Infect Dis. 2023. PMID: 37565522 Free PMC article.
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA, McLaughlin JM, Malden D, Hong V, Puzniak L, Ackerson BK, Lewin BJ, Kim JS, Shaw SF, Takhar H, Jodar L, Tartof SY. Lewnard JA, et al. Lancet Infect Dis. 2023 Jul;23(7):806-815. doi: 10.1016/S1473-3099(23)00118-4. Epub 2023 Mar 15. Lancet Infect Dis. 2023. PMID: 36933565 Free PMC article.
5,623 results